This is a website for healthcare professionals.
Publications
AVISE Lupus is indicated for the diagnosis of suspected SLE patients. AVISE CTD is indicated for differential diagnosis of autoimmune connective tissue diseases.
Clinical Validity
Putterman C, et al. Lupus Science & Medicine. 2014. Cell bound complement activation products in systemic lupus erythematosus.
Ramsey-Goldman R, et al. Arthritis & Rheumatology. 2019. Complement activation occurs in patients with probable systemic lupus erythematosus and may predict progression to ACR classified SLE.
Wallace D, et al. Lupus Science & Medicine. 2016. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.
Clinical Utility
Wallace D, et al. Lupus Science & Medicine. 2019. Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE.
Liang E, et al. Lupus Science & Medicine. 2020. Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression.
Mossell J, et al. Open Rheumatology Journal. November 2016. The AVISE Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus.
Health Economic Outcome Research
Clarke et al. ACR Open Rheumatology. 2020. Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using a Multivariate Assay Panel (MAP).
Analytical Validity
Dervieux et al. Journal of Immunological Methods. 2017. Validation of multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus.
SLE Review Articles
Mosca M, et al. Arthritis & Rheumatology. 2019. How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria.
Meacock R, Dale N, Harrison MJ et al. Pharmacoeconomics. 2013. The humanistic and economic burden of systemic lupus erythematosus: A systematic review. Pharmacoeconomics.
Case Study
Lamichhane D, Weinstein A et al. Lupus. 2016. Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPS).
Medical Society Guidelines
Aggarwal, Rohit et al. Arthritis Care & Research. 2015. Distinctions between diagnostic and classification criteria?
Clinical Validity
Manzi et al. Arthritis & Rheumatism. 2004. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus.
Kao AH et al. Arthritis & Rheumatism. 2010. Navratil JS, Ruffing MJ, et al. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Arthritis Rheum.
Liu CC, Kao AH, Hawkins DM, Manzi S, Sattar A, Wilson N, Ahearn JM et al. Clinical and Translational Science. 2009. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus. Clin Transl Sci.
Yang et al. Rheumatology. 2009. Usefulness of erythrocyte-bound C4d as a biomarker to predict disease activity in patients with systemic lupus erythematosus.
Analytical Validity
Dervieux T et al. Journal of Immunological Methods. 2017. Validation of multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus.
CB-CAPs Review Articles
Ramsey-Goldman R, Li J, Dervieux T, et al. Lupus Science and Medicine. 2017. Cell-bound complement activation products in SLE. Lupus Science & Medicine.
Ahearn et al. Expert Review of Clinical Rheumatology. 2017. Cell-bond complement activation products as lupus biomarkers: diagnosis, monitoring and stratification.
PC4d is indicated for diagnosed SLE patients as a marker associated with thrombosis.
Clinical Validity
Elisabet Svenungsson et al. Rheumatology. 2020. Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus.
Petri MA, Conklin J, O'Malley T, et al. Lupus Science and Medicine. 2019. Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE Lupus Science & Medicine.
Kao AH, McBurney CA, Sattar A, Lertratanakul A, Wilson NL, Rutman S, Paul B, Navratil JS, Scioscia A, Ahearn JM, Manzi S. et. al. Transl. Stroke Research. 2014. Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus.
Avise MTX is indicated for RA patients receiving Methotrexate therapy as an objective measure of therapeutic exposure.
Clinical Validity
Takahashi C, Kaneko Y, Okano Y, et al. RMD Open. 2017. Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study.
Dervieux et al. Rheumatology. 2010. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis.
Dervieux et al. Annals of the Rheumatic Diseases. 2005. Pharmacogentic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentered cross-sectional observation study.
Dervieux et al. Arthritis and Rheumatology. 2006. Pharmacogenomic and Metabolic Biomarkers in the Folate Pathway and Their Association With Methotrexate Effects During Dosage Escalation in Rheumatoid Arthritis.
AVISE MTX Review Articles
Braun J. et al. Therapeutic Advances in Musculoskeletal Disease. 2011. Methotrexate: Optimizing the Efficacy in Rheumatoid Arthritis. Therapeutic Advances in Musculoskeletal Disease.
Kremer J. et al. Arthritis & Rheumatology. 2004. Toward a Better Understanding of Methotrexate. Arthritis and Rheum.
Analytical Validity
Kelley Brady et al. The Journal of Applied Laboratory Medicine. 2019. Transition of Methotrexate Polyglutamate Drug Monitoring Assay from Venipuncture to Capillary Blood-Based Collection Method in Rheumatic Diseases.
AVISE HCQ is indicated for SLE patients receiving Hydroxychloroquine therapy as an objective measure of therapeutic exposure.
Clinical Validity
Petri et al. Arthritis & Rheumatology. 2019. Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.
Costedoat-Chalumeau et al. American Society for Clinical Pharmacology and Therapeutics. 2017. A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires.
Costedoat Chalumeau N et al. Annals of the Rheumatic Diseases. 2013. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Costedoat-Chalumeau N et al. Very Low Blood Hydroxychloroquine Concentration As an Objective Marker of Poor Adherence to Treatment of Systemic Lupus Erythematosus.
AVISE HCQ Review Articles
Garg et al. Arthritis Care & Research. 2020. The Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.
Laura Durcan, William A. Clarke, Laurence S. Magder, Michelle Petri et al. The Journal of Rheumatology. 2015. Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence
Analytical Validation
Qu et al. J Pharm Biomed Anal. 2017. Capillary blood collected on volumetric absorptive microsampling (VAMS) device for monitoring hydroxychloroquine in rheumatoid arthritis patients.
Arriens C, Alexander RV, Narain S, et al. Lupus Science & Medicine. 2020. Cell-bound complement activation products associate with lupus severity in SLE. Lupus Science & Medicine.
Hui-Yen et al. Lupus. 2018. Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity.
Abstracts
Petri M, Li J, Conklin J, O'Malley T, Ligayon J, Wolover L, Dervieux T. et al. Arthritis Rheumatol. 2020. Role of Platelet C4d in Thrombosis and Lupus Nephritis [abstract].
Gartshteyn Y, Mor A, Shimbo D, Khalili L, Kapoor T, Geraldino-Pardilla L, Alexander R, Dervieux T, Askanase A. et al. Arthritis Rheumatol. 2020. Platelet-bound C4d Is Associated with Platelet Activation and Arterial Thrombotic Events [abstract].
Gartshteyn Y, Alexander R, Conklin J, Dervieux T, Askanase A. et al. Arthritis Rheumatol. 2020. Platelet-bound C4d Is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE [abstract].
Gartshteyn Y, Mor A, Geraldino L, Kapoor T, Chen T, Dervieux T, Askanase A. et al. Arthritis Rheumatol. 2019. Platelet Bound Complement Split Product (PC4d) May Be a Marker of Platelet Activation and Cardiovascular Events in Systemic Lupus Erythematosus [abstract].
Petri M, Li J, Brady K, Conklin J, O'Malley T, Dervieux T. et al. Arthritis Rheumatol. 2020. Agreement of Hydroxychloroquine Blood Levels Between a University and Commercial Laboratory [abstract].
Balbi V, Silva C, Pedrosa T, Pereira R, Campos L, Leon E, Duarte N, Carvalho V, Pasoto S, Rosario D, Brandao L, Bonfa E, Aikawa N. et al. Arthritis Rheumatol. 2020. Hydroxychloroquine Blood Levels Predicts 6-Months Disease Activity in Juvenile Lupus Nephritis [abstract].
Dervieux T, Kremer J, Brady K, Takahashi C, Takeuchi T, Kaneko Y. et al. Arthritis Rheumatol. 2019. Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate [abstract].
Garg S, Unnithan R, Hansen K, Costedoat-Chalumeau N, Bartels C. et al. Arthritis Rheumatol. 2019. Meta-Analysis Examining the Clinical Significance of Monitoring of Hydroxychloroquine Levels in SLE [abstract].
Petri M, Elkhalifa M, Goldman D, Magder LS, Singh M. et al. Arthritis Rheumatol. 2018. Hydroxychloroquine Blood Levels Show Significant Trend Test for Risk of Retinopathy [abstract].
Dervieux T, Kremer J, Brady K, Takahashi C, Takeuchi T, Kaneko Y. et al. Arthritis Rheumatol. 2019. Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian Rheumatoid Arthritis Patients Starting Methotrexate [abstract].
Dervieux T, Grosjean M, Jiang C, Brady K, Schmiegelow K, Kremer J, Yang J. et al. Arthritis Rheumatol. 2018. Genetic Polymorphism in Dihydrofolate Reductase Impacts Methotrexate Polyglutamation in Adult Rheumatoid Arthritis [abstract].
Dervieux T, Kremer JM, O'Malley T, Kivitz AJ, Conklin J, Weinblatt M. et al. Arthritis Rheumatol. 2016. Differing Contribution of Methotrexate Polyglutamation to Infliximab and Adalimumab Exposure As Compared to Etanercept [abstract].
Methotrexate polyglutamates (MTXPGs)
Brady K, et al. American Association for Clinical Chemistry. 2019. Transition of Methotrexate Polyglutamate Drug Monitoring Assay from Venipuncture to Capillary Blood-Based Collection Method in Rheumatic Diseases.
Dervieux T, et al. Annals of the Rheumatic Diseases 2018. Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept.
Dervieux T, et al. Annals of the Rheumatic Diseases 2012. Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis.
Dervieux T, et al. Annals of the Rheumatic Diseases. 2005. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study.
Dervieux T, et al. Arthritis & Rheumatism. 2006. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.
Kremer J. Arthritis & Rheumatism. 2004. Toward a better understanding of methotrexate.
Dervieux T, et al. Clinical Chemistry. 2003. HPLC Determination of Erythrocyte Methotrexate Polyglutamates after Low-Dose Methotrexate Therapy in Patients with Rheumatoid Arthritis.
Anti-Carbamylated Protein Antibodies (Anti-CarP)
Weinstein A, et al. The Journal of Rheumatology. 2019. Reevaluating Serologic Markers of Poor Prognostic Factors in Rheumatoid Arthritis.
Shi J, et al. PNAS. 2011. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage.
Abstracts
An Evaluation of the Economic Impact of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using Complement C4D Activation Products in a Multivariate Assay.
ACR Chicago 2018. Capillary Blood Based Methotrexate Polyglutamate Assay for Monitoring Low Dose Methotrexate Therapy in Rheumatic Diseases.
ACR Chicago 2018. Genetic Polymorphism in Dihydrofolate Reductase Impacts Methotrexate Polyglutamation in Adult Rheumatoid Arthritis.
ACR Chicago 2018 Complement C4d Split Products in Combination With lupus Anticoagulant and Low Complement Associate With Thrombosis in Systemic lupus erythematosus.
ACR San Diego 2017. Abnormalities in Complement System are Related to Disease Severity Index in Systemic lupus erythematosus.
ACR Chicago 2018 Diagnostic Performances of Antibodies Against Carbamylated Proteins in U.S. Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases
ACR San Diego 2017. Complement Activation in Peripheral Blood in Relation to lupus, Antiphospholipid and Rheumatoid Arthritis Autoantibodies: Insights From Clinical Laboratory Evaluations.
ACR San Diego 2017. A Panel of lupus Biomarkers for the Monitoring of systemic lupus erythematosus: Performance Characteristics in Distinct SLE Cohorts.
ACR San Diego 2017. Abnormalities in Complement System are Related to Disease Severity Index in Systemic lupus erythematosus.
ACR San Diego 2017. Cell bound Complement Activation Products Distinguish systemic lupus erythematosus From Other Diseases Among Patients With High Antinuclear Antibody Titers and Normal Complement.
ACR Chicago 2018 Diagnostic Performances of Antibodies Against Carbamylated Proteins in U.S. Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases.
ACR San Diego 2017. Complement Activation in Peripheral Blood in Relation to lupus, Antiphospholipid and Rheumatoid Arthritis Autoantibodies: Insights From Clinical Laboratory Evaluations.
ACR San Diego 2017. A Panel of lupus Biomarkers for the Monitoring of systemic lupus erythematosus: Performance Characteristics in Distinct SLE Cohorts.
ACR San Diego 2017. Cell bound Complement Activation Products Distinguish systemic lupus erythematosus From Other Diseases Among Patients With High Antinuclear Antibody Titers and Normal Complement.